Capsugel Installs New Encapsulation Unit for DPI Applications at Bend, Oregon Facility

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-04-05-2017
Volume 12
Issue 4

The newly installed Harro Hӧfliger encapsulation unit expands Capsugel’s clinical- and commercial-scale capacity for dry powder inhalation projects.

Capsugel has expanded its late-stage inhalation capabilities to advance dry powder inhalation (DPI) concepts through late-stage clinical trial and commercial production. A new Harro HÓ§fliger Modu-C MS encapsulation unit has been installed and validated at its Bend, Ore. facility that includes specialized drum-dosing technology for DPI development projects using spray-dry processing.

The equipment has an operational capacity of more than 72,000 capsules per hour. The technology provides 100% monitoring of dosed powder mass, fill weight ranges between 5 mg and 50 mg, and dose accuracy of <3% relative standard deviation.

The unit complements Capsugel’s Xcelodose 600S equipment that supports capsule filling for Phase 1 and Phase 2 trials. Capsugel’s capabilities for DPI formulations include spray drying for all clinical phases and commercial manufacturing, formulation development and scale-up, phase-appropriate encapsulation and full aerosol analytical capabilities in development and GMP.

Source: Capsugel

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Related Content